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tional study of schizophrenic patients who commence RLAI.
Data collected retrospectively (12 months) and prospectively (2
years) includes: patient demographics, medications, hospitalisa-
tions, Clinical Global Impression-Severity (CGI-S), GAF and
adverse events. A general linear model (GLM) was used to deter-
mine the impact of baseline characteristics on GAF improvement
over 12 months. RESULTS: Data from 399 patients from 15 psy-
chiatric services were available for this analysis. The average age
was 38.9 ± 13.2 years (mean ± SD), the mean duration of illness
was 12.0 ± 9.6 years, and 68% were male. The baseline CGI-S
was 4.5 ± 1.0 and GAF was 42.4 ± 14.1. The greatest improve-
ments in GAF score occurred in the ﬁrst 3-months following
switch to RLAI, however, signiﬁcant improvements also occurred
between 3- and 6-months (baseline: 42.8 ± 14.3; 3-months 50.3
± 15.5; 6-months 53.0 ± 15.3, p < 0.001 [0–3 months, and 3–6
months], n = 328). Those patients with baseline GAF scores less
than 30 were more likely to show greater improvements in their
GAF functioning over the 12-month period (GLM coefﬁcient
28.4 [CI: 22.2–34.7, p < 0.001]), as were patients with baseline
GAF scores of 30–60 (GLM coefﬁcient 14.5 [CI: 8.8–20.1, p <
0.001]). Patients whose last does of RLAI was 25 mg and who
stayed on RLAI for 12-months were more likely to have positive
changes in their GAF over the 12-month period (GLM coefﬁ-
cient 5.3 [CI: 1.8–8.8 and 5.0 [CI: 1.7–8.4, p ∼ 0.003], respec-
tively). CONCLUSIONS: Patients with a low GAF score at
baseline, and those who stayed on 25 mg of RLAI are more likely
to show positive improvements in GAF functioning when treated
over a 12-month period. The most signiﬁcant improvements in
functioning are seen in the ﬁrst six months of treatment.
SZ4
A CARER’S PERSPECTIVE ON THE VALUATION OF
SCHIZOPHRENIA-RELATED HEALTH STATES USING THE
ASSESSMENT OF QUALITY OF LIFE QUESTIONNAIRE AND
THE EQ5D
Adams J1, Le Reun C1, Crowley S2, Eggleston A3
1M-TAG Pty Ltd, Chatswood, NSW, Australia, 2Program Evaluation
Unit, University of Melbourne; Janssen-Cilag Pty Ltd, North Ryde,
NSW, Australia, 3Janssen-Cilag Pty Ltd, North Ryde, NSW, Australia
OBJECTIVE: To obtain a carer’s perspective on the valuation of
eight schizophrenia-related health states using two multi-
attribute utility instruments, the Assessment of Quality of Life
Questionnaire (AQoL), and the EQ5D. METHODS: Eight schiz-
ophrenia-related health state scenarios based on severity of
symptoms and medication side effects were presented to 64
carers of patients with schizophrenia in face-to-face question-
naires. Scenarios were: (A) “good” function with no movement
disorders (extrapyramidal symptoms); (B) “good” function with
movement disorders; (C) “poor” function with no movement
disorders; (D) “poor” function with movement disorders; (E)
hospitalised relapse with no movement disorders; (F) hospi-
talised relapse with movement disorders; (G) post-hospitalisation
with no movement disorders; and (H) post-hospitalisation with
movement disorders. The carers valued each health state using
the AQoL and the EQ5D from the carer and patient perspec-
tives. RESULTS: When carer’s were asked to assess their quality
of life when the person they cared for was in the various health
states, the mean utility values from the AQoL ranged from 0.56
± 0.26 (SD), for Scenario A, to 0.22 ± 0.25, for Scenario F. Mean
utility values for the health states from the EQ5D ranged from
0.76 ± 0.19, for Scenario A, to 0.29 ± 0.42, for Scenario F. When
the carer’s were asked to assess the health state scenarios from
a patient’s perspective, the mean utility values from the AQoL
ranged from 0.37 ± 0.23, for Scenario A, to 0.04 ± 0.19, for Sce-
nario F. Mean utility values for the health states from the EQ5D
ranged from 0.70 ± 0.28, for Scenario A, to 0.03 ± 0.43, for Sce-
nario F. CONCLUSION: From both perspectives, the rank order
of utility values was consistent with the severity of symptoms,
with more severe symptoms producing lower scores. Scenarios
that involved patients experiencing extrapyramidal symptoms or
hospitalisation produced lower utility values.
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OBJECTIVE: To evaluate if the reimbursement of simvastatin is
justiﬁed in the secondary and primary prevention of coronary
heart disease (CHD) in Poland in 2006. METHODS: Life-table
method in secondary prevention and Markov model in primary
prevention were used. Population characteristics and outcomes
were based on 4S and HPS trials. The analysis in the primary
prevention were performed in two groups with 3% and 5% 5-
year risk of cardiovascular death (CVD) to comply with EURO-
SCORE algorithm. Direct costs of CHD and stroke were
projected over lifetime from Polish National Health Fund per-
spective. Costs, epidemiological data and quality of life weights
(primary prevention) were derived from published sources. Costs
and effects were discounted at 5% annually. RESULTS: LYG in
the secondary prevention was calculated as €365 for 58-year old
men and €613 for 60-year old women. Cost of QALY in the
primary prevention ranged from €2154 for 50-year old men to
€2595 for 65-year old men in the group with 3% risk and from
€1544 to €1796 for 5% risk, well within implicit limits at
roughly €15,000. Results for women were very close to men but
were less robust due to uncertainty in preventing CVD death.
CONCLUSION: Reimbursement of simvastatin in Poland is eco-
nomically justiﬁed regardless of age of initiation of The rapy and
sex. Raising the level of reimbursement from current 70% to
100% will increase availability for all, who may beneﬁt from
The rapy but cannot afford co-payment. The analysis may help
to develop guidelines for primary prevention using EURO-
SCORE risk system.
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OBJECTIVES: To compare the effectiveness of statins with
respect to LDL-cholesterol reduction and cholesterol goal attain-
ment in a real life setting. METHODS: From the PHARMO
database (population > 2 million) we selected new statin users
between December 31, 2002 and January 1, 2005 with LDL-
cholesterol measurements both at baseline and follow-up
(between 30 and 365 days after statin initiation). Hospital
admission and pharmacy data were used to allocate individuals
to primary or secondary prevention categories. The effectiveness
of different statins was compared with respect to LDL-C reduc-
tion (linear regression) and 2003 European guideline cholesterol
goal attainment (logistic regression), adjusting for gender, age,
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baseline cholesterol levels and relevant co-morbidity. RESULTS:
A total of 2341 patients were identiﬁed, of these 644 were initi-
ated on rosuvastatin (93% on 10 mg), 606 on atorvastatin (53%
on 10 mg, 39% on 20 mg), 613 on simvastatin (70% on 20 mg),
440 on pravastatin (79% on 40 mg) and 38 on ﬂuvastatin (79%
on 80 mg). Secondary prevention accounted for approximately
30% of patients. Average percent LDL-C reductions were 48.0
(CI95%: 46.6–49.5), 41.7 (CI95%: 39.9–43.4), 38.7 (CI95%:
37.3–40.0), 32.0 (CI95%: 30.1–33.9), and 29.7 (CI95%:
23.9–35.5) for rosuvastatin, atorvastatin, simvastatin, pravas-
tatin and ﬂuvastatin respectively. The proportion of patients
attaining cholesterol goals was 75% for rosuvastatin, 68% for
atorvastatin, 56% for simvastatin, 42% for pravastatin, and
34% for ﬂuvastatin. After adjustment for risk factors the use of
rosuvastatin was signiﬁcantly associated with both greater LDL-
C reduction (mean differences 5.4% to 18.3%, all p < 0.001),
and with increased goal attainment (odds ratios 0.60 to 0.11, all
p < 0.001) compared to users of other statins. CONCLUSION:
We found evidence that in a real life setting, both percentage
LDL-C reduction and the proportion of patients attaining 2003
European cholesterol goals is signiﬁcantly greater among users
of rosuvastatin compared to other statins. Results are consistent
with those reported in clinical trials.
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OBJECTIVE: To examine Medicare resource utilization and
costs among patients with congestive heart failure (CHF) over
the course of one year after an initial CHF hospital discharge.
METHODS: Statistical analyses were conducted on Medicare
Standard Analytic Files. A cohort of patients with an initial inpa-
tient hospitalization for CHF between January 1, 1999 and
December 31, 2000 were identiﬁed and followed for a period of
one year. Outcomes assessed included the number of readmis-
sions (CHF-related and all-cause) and emergency department
(ED) visits; the mean time to each readmission/visit; mortality
following discharge; number and timing of physician ofﬁce visits;
and total charges. Multivariate regression analyses were con-
ducted to assess the likelihood of hospital readmission, likeli-
hood of death, and total charges adjusting for patient
characteristics and compliance with routine care. RESULTS: A
cohort of 690,800 patients (weighted) was identiﬁed. Within one
year of their initial hospitalization, approximately 20 percent of
patients (136,460; 19.75%) were readmitted for CHF and over
one-half (350,660; 50.76%) were readmitted for all causes. The
time-to-event analysis revealed that increasing the time to ﬁrst
readmission decreases the overall number of readmissions and
associated costs. Over 50% of patients visited the ED within 3
months of hospital discharge. The one-year mortality rate was
31.4%. The patient population that was readmitted within 30
days of initial hospital discharge accumulated the highest total
charges over the course of the year (mean = $66,639). In the mul-
tivariate model, the main cost drivers were the number of hos-
pital readmissions and death anytime within the year (potentially
due to high end-of-life costs). CONCLUSIONS: The large pro-
portion of hospital readmissions and ED visits occurring shortly
after discharge suggests that many patients are not sufﬁciently
managed once outside the hospital. Increased compliance with
physician visits could help decrease the overall number of both
CHF-related and all-cause readmissions.
CV8
REAL WORLD MORTALITY OF THE HYPERTENSIVE PATIENT
AS DEFINED IN THE ASCOT-LLA
F Bobadilla J1, Sicras A2, Moreno R3, García Puig J4, García M5,
Navarro R2, Soto J1
1Pﬁzer Spain, Alcobendas, Madrid, Spain, 2Badalona Servicios
Asistenciales, Badalona, Barcelona, Spain, 3San Carlos Clinical Hospital,
Madrid, Madrid, Spain, 4La Paz University Hospital, Mardid, Madrid,
Spain, 5Euroclin Institute, Alcobendas, Madrid, Spain
All cause mortality in the placebo group of ASCOT-LLA (Anglo-
Scandinavian Cardiac Outcomes Trial-Lipid-Lowering arm) was
1.28%. ASCOT-LLA included hypertensive patients (HP) in
primary prevention, with TC ≥ 6.5 mmol/L, not treated with
statins and with at least 3 cardiovascular risk factors (CVRF). A
lower CV morbimortality with atorvastatin ten mg vs placebo
was demonstrated. OBJECTIVES: Evaluate the real world mor-
tality of HP as deﬁned in ASCOT-LLA in a Mediterranean pop-
ulation of HP not treated with statins. METHODS: Patients
from seven primary care centres with a diagnosis of HT (CIAP
= K86-K87) were included in a multicentric registry of one year
follow-up (2004–2005) (n = 6309 patients). Main analysed vari-
ables were: basal age-sex, diabetes mellitus, stroke, smoking,
TC/HDL-ratio and all cause mortality (2004). RESULTS: Of the
6309 patients, 2528 (40%) had a history of CHD and/or heart
failure (HF) and/or TC > 6.5 mmol/L and/or statin treatment and
were excluded from the analysis. In the remaining 3781, CVFR
≥ 3 was conﬁrmed in 831. The annual mortality of these patients
was 2.89%, greater than ASCOT-LLA placebo group. In the
group of 3781 patients with no history of cardiac disease nor
TC > 6.5 mmol/L and without statin treatment, those with CVRF
≥ 3 had a higher mortality (2.89%) vs CVRF < 3 (1.86%)
(Fisher: p = 0.0497; χ2 : p = 0.0795). A signiﬁcant relationship
was demonstrated among CVRF number and mortality: 0
CVRF-0% mortality; 1 CVRF:1.4% mortality; 2 CVRF:2.7%
mortality; 3 CVRF:2.0% mortality; 4 CVRF:4.8% mortality; ≥5
CVRF:5.9% mortality (Mantel-Haenzel test: p = 0.003). CON-
CLUSIONS: Our data suggest that real world mortality of
ASCOT-like hypertensives in a Mediterranean population is
greater than the mortality found in the ASCOT (2.89% vs.
1.29%). A signiﬁcant relationship was demonstrated among
CVRF and mortality. Our data also suggest that the presence of
CVRF ≥ 3 indicates a high mortality risk.
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OBJECTIVE: Rimonabant, the ﬁrst selective CB-1 receptor
blocker, has proven effective in improving cardiometabolic risk
factors and reducing weight in overweight and obese individu-
als. This study evaluated its cost-effectiveness in patients with a
BMI > 27 kg/m2 in the UK. METHODS: A discrete event simu-
lation was created to take into account multiple time-dependent
risk factors—it predicts changes in anthropomorphic and phys-
iologic parameters based on analysis of pooled RIO trials data,
while simultaneously predicting onset of diabetes, cardiovascu-
